Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 55, Issue 19, Pages 8515-8523Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm301074n
Keywords
-
Categories
Funding
- National Health and Medical Research Council (NHMRC Program) Australia [496600]
- Grants-in-Aid for Scientific Research [23790144] Funding Source: KAKEN
Ask authors/readers for more resources
Infection with group A streptococcus (GAS) can result in a number of diseases, some of which are potentially life-threatening. The oral-nasal mucosa is a primary site of GAS infection, and a mucosally active vaccine candidate could form the basis of an antidisease and transmission-blocicing GAS vaccine. In the present study, a peptide from the GAS M protein (J14) representing a B cell epitope was incorporated alongside a universal T cell helper epitope and a Toll-like receptor 2 targeting lipid moiety to form lipopeptide constructs. Through structure activity studies, we identified a vaccine candidate that induces J14-specific mucosal and systemic antibody responses when administered intranasally without additional adjuvants. The systemic antibodies elicited were capable of inhibiting the growth of GAS. In addition, J14-specific mucosal antibodies corresponded with reduced throat colonization after respiratory GAS challenge. These preclinical experiments show that this lipopeptide could form the basis of an optimal needle-free mucosal GAS vaccine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available